The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Selinexor in the treatment of R/R myeloma: combination strategies and optimizing therapy
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the potential of selinexor in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), highlighting the possibility of using it as monotherapy or in combination with other agents. Dr Cerchione notes that selinexor may address an unmet need, particularly in patients with limited treatment options following treatment failure with immunotherapeutic approaches. He also mentions the ongoing exploration of biomarkers for optimizing selinexor’s efficacy and anticipates further advances through clinical trials. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
